{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:32:19Z","timestamp":1791484339984,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13760-025-02864-2","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:29:25Z","timestamp":1755012565000},"page":"747-756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of aripiprazole and valbenazine in the treatment of tourette syndrome: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5653-1931","authenticated-orcid":false,"given":"Muneeb Ahmad","family":"Muneer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ume","family":"Habiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shajjia","family":"Shehzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Washija","family":"Batool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawood","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Khizar","family":"Kirmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohaib Hassan","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areeb","family":"Amjad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameer","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Faizan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad Siddique","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Tehseen","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"2864_CR1","unstructured":"Tourette Syndrome What Is It,\u00a0(2025) Symptoms & Treatment. https:\/\/my.clevelandclinic.org\/health\/diseases\/5554-tourette-syndrome"},{"key":"2864_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.109675","volume":"95","author":"JLS Levine","year":"2019","unstructured":"Levine JLS, Szejko N, Bloch MH (2019) Meta-analysis: adulthood prevalence of tourette syndrome. Prog Neuropsychopharmacol Biol Psychiatry 95:109675","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2864_CR3","unstructured":"Tourette Syndrome (2025) National institute of neurological disorders and Stroke.\u00a0https:\/\/www.ninds.nih.gov\/health-information\/disorders\/tourette-syndrome"},{"key":"2864_CR4","doi-asserted-by":"crossref","unstructured":"Nomura Y (2021) Pharmacological therapy for tourette syndrome: what medicine can do and cannot do. Biomed J 45(2):229. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9250092\/","DOI":"10.1016\/j.bj.2021.09.002"},{"issue":"6","key":"2864_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jpsychores.2009.08.003","volume":"67","author":"V Eapen","year":"2009","unstructured":"Eapen V, \u010crn\u010dec R (2009) Tourette syndrome in children and adolescents: special considerations. J Psychosom Res 67(6):525\u2013532","journal-title":"J Psychosom Res"},{"key":"2864_CR6","doi-asserted-by":"crossref","unstructured":"Eapen V, Cavanna AE, Robertson MM (2016 ) Comorbidities social impact, and quality of life in tourette syndrome. Front Psychiatry 7. https:\/\/pubmed.ncbi.nlm.nih.gov\/27375503\/","DOI":"10.3389\/fpsyt.2016.00097"},{"key":"2864_CR7","doi-asserted-by":"crossref","unstructured":"Novotny M, Valis M, Klimova B (2018) Tourette syndrome: a mini-review. Front Neurol 9:325978. www.frontiersin.org","DOI":"10.3389\/fneur.2018.00139"},{"key":"2864_CR8","doi-asserted-by":"crossref","unstructured":"Quezada J, Coffman KA (2018) Current approaches and new developments in the pharmacological management of tourette syndrome. CNS Drugs 32(1):33\u201345. https:\/\/pubmed.ncbi.nlm.nih.gov\/29335879\/","DOI":"10.1007\/s40263-017-0486-0"},{"key":"2864_CR9","doi-asserted-by":"crossref","unstructured":"Kim ES, Valbenazine (2017) First global approval. Drugs 77(10):1123\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/28578484\/","DOI":"10.1007\/s40265-017-0770-9"},{"key":"2864_CR10","doi-asserted-by":"crossref","unstructured":"Cox JH, Cavanna AE (2021) Aripiprazole for the treatment of tourette syndrome. Expert Rev Neurother 21(4):381\u201391. https:\/\/pubmed.ncbi.nlm.nih.gov\/33612035\/","DOI":"10.1080\/14737175.2021.1893693"},{"key":"2864_CR11","doi-asserted-by":"crossref","unstructured":"Farber RH, Angelov A, Kim K, Carmack T, Thai-Cuarto D, Roberts E (2021) Clinical development of valbenazine for tics associated with Tourette syndrome. Expert Rev Neurother 21(4):393\u2013404. https:\/\/pubmed.ncbi.nlm.nih.gov\/33682568\/","DOI":"10.1080\/14737175.2021.1898948"},{"key":"2864_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"2864_CR13","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions (2025) Cochrane.\u00a0https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook"},{"key":"2864_CR14","unstructured":"Study Details (2025) Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome ClinicalTrials.gov .\u00a0https:\/\/clinicaltrials.gov\/study\/NCT03530293"},{"key":"2864_CR15","unstructured":"Study Details (2025) Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome ClinicalTrials.go. https:\/\/clinicaltrials.gov\/study\/NCT02581865"},{"key":"2864_CR16","unstructured":"Study D (2025) Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03325010"},{"key":"2864_CR17","unstructured":"Study Details (2025) Efficacy & safety study of once-weekly oral aripiprazole in children and adolescents with Tourette\u2019s disorder ClinicalTrials.gov.\u00a0https:\/\/clinicaltrials.gov\/study\/NCT01418339"},{"key":"2864_CR18","unstructured":"Study Details (2025) Efficacy & safety study of once-weekly oral aripiprazole in children and adolescents with Tourette\u2019s disorder (TD) ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01418352"},{"key":"2864_CR19","unstructured":"Study Details (2025) Study evaluating the safety and efficacy of fixed-dose once-daily oral aripiprazole in children and adolescents With Tourette\u2019s disorder ClinicalTrials.gov.\u00a0https:\/\/www.clinicaltrials.gov\/study\/NCT01727700"},{"key":"2864_CR20","doi-asserted-by":"crossref","unstructured":"He F, Luo J, Huang Y, Hao Y, Sun L, Ke X et al (2024) Randomized, double-blind, placebo-controlled trial of aripiprazole oral solution in children and adolescents with Tourette\u2019s disorder. Child Adolesc Psychiatry Ment Health 18(1). https:\/\/pubmed.ncbi.nlm.nih.gov\/39026306\/","DOI":"10.1186\/s13034-024-00764-6"},{"key":"2864_CR21","unstructured":"Study Details (2021) Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02679079"},{"key":"2864_CR22","doi-asserted-by":"crossref","unstructured":"Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L et al (2011) European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry 20(4):173\u201396. https:\/\/pubmed.ncbi.nlm.nih.gov\/21445724\/","DOI":"10.1007\/s00787-011-0163-7"},{"key":"2864_CR23","doi-asserted-by":"crossref","unstructured":"Peckham AM, Nicewonder JA (2019) VMAT2 Inhibitors for tardive dyskinesia-practice implications. J Pharm Pract 32(4):450\u20137. https:\/\/pubmed.ncbi.nlm.nih.gov\/29455579\/","DOI":"10.1177\/0897190018756512"},{"key":"2864_CR24","doi-asserted-by":"crossref","unstructured":"Makhoul K, Jankovic J (2023) Real-world experience with VMAT2 inhibitors in Tourette syndrome. J Neurol 270(9):4518\u201322.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/37301806\/","DOI":"10.1007\/s00415-023-11769-0"},{"issue":"3","key":"2864_CR25","doi-asserted-by":"publisher","first-page":"e212030","DOI":"10.1001\/jamanetworkopen.2021.2030","volume":"4","author":"J Jankovic","year":"2021","unstructured":"Jankovic J, Jimenez-Shahed J, Budman CL et al (2021) Efficacy and safety of valbenazine in children and adolescents with tourette syndrome: a randomized clinical trial. JAMA Netw Open 4(3):e212030. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.2030","journal-title":"JAMA Netw Open"},{"key":"2864_CR26","doi-asserted-by":"crossref","unstructured":"Chou CY, Agin-Liebes J, Kuo SH (2023) Emerging therapies and recent advances for Tourette syndrome. Heliyon 9(1):e12874. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9860289\/","DOI":"10.1016\/j.heliyon.2023.e12874"},{"key":"2864_CR27","doi-asserted-by":"crossref","unstructured":"Waldon K, Hill J, Termine C, Balottin U, Cavanna AE (2013) Trials of pharmacological interventions for Tourette syndrome: a systematic review. Behavioural neurology 26(4):265\u201373. https:\/\/pubmed.ncbi.nlm.nih.gov\/22713420\/","DOI":"10.1155\/2013\/626410"},{"key":"2864_CR28","doi-asserted-by":"crossref","unstructured":"Hollis C, Pennant M, Cuenca J, Glazebrook C, Kendall T, Whittington C et al (2016) Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis. Health Technol Assess 20(4). https:\/\/pubmed.ncbi.nlm.nih.gov\/26786936\/","DOI":"10.3310\/hta20040"},{"key":"2864_CR29","doi-asserted-by":"crossref","unstructured":"Yang CS, Huang H, Zhang LL, Zhu CR, Guo Q (2015) Aripiprazole for the treatment of tic disorders in children: a systematic review and meta-analysis. BMC Psychiatry 15(1):179. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4518630\/","DOI":"10.1186\/s12888-015-0504-z"},{"key":"2864_CR30","doi-asserted-by":"crossref","unstructured":"Besag FMC, Vasey MJ, Lao KSJ, Chowdhury U, Stern JS (2021) Pharmacological treatment for Tourette syndrome in children and adults: What is the quality of the evidence? A systematic review. J Psychopharmacol 35(9):1037\u201361. https:\/\/pubmed.ncbi.nlm.nih.gov\/34286606\/","DOI":"10.1177\/02698811211032445"},{"key":"2864_CR31","doi-asserted-by":"crossref","unstructured":"Yang C, Yi Q, Zhang L, Cui H, Mao J (2019) Safety of aripiprazole for tics in children and adolescents: A systematic review and meta-analysis. Medicine 98(22). https:\/\/pubmed.ncbi.nlm.nih.gov\/31145316\/","DOI":"10.1097\/MD.0000000000015816"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02864-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-025-02864-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02864-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:03:52Z","timestamp":1785218632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-025-02864-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2864"],"URL":"https:\/\/doi.org\/10.1007\/s13760-025-02864-2","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing financial or non-financial interests related to the work presented in this study.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}